Cancer, Diabetes Drugs — And Botox — On List For Medicare Price Negotiations
CMS has identified 15 prescription drugs to target for lower prices in 2028: Anoro Ellipta, Biktarvy, Botox, Cimzia, Cosentyx, Entyvio, Erleada, Kisqali, Lenvima, Orencia, Rexulti, Trulicity, Verzenio, Xeljanz, and Xolair. Plus, the fallout from a largely flat Medicare Advantage reimbursement increase.